Onyx Pharmaceuticals Inc., the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Inc. Onyx surged in early trading.
Read more: Bloomberg news
Interactive Chart
Choose from over 7000 stocks and watch the chart real-time. Requires Microsoft Silverlight.
|
|
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment